Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichiro Eguchi

Showing results (71-80 of 239) with videos related to

Pageof 24
Sort By:
Digestion|November 19, 2018
Risk Factors for Delayed Hemorrhage after Colonic Endoscopic Mucosal Resection in Patients Not on Antithrombotic Therapy: Retrospective Analysis of 3,844 Polyps of 1,660 PatientsSanae Tsuruta, Naoyuki Tominaga, Shinichi Ogata, et al.
Biochimica Et Biophysica Acta|May 18, 2010
Regulation of tumor suppressor PDCD4 by novel protein kinase C isoformsMayumi Nakashima, Hiroshi Hamajima, Jinghe Xia, et al.
Clinical Biochemistry|May 7, 2014
Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver diseaseMasato Yoneda, Emmanuel Thomas, Yoshio Sumida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 31, 2015
Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatmentSaori Kamachi, Toshihiko Mizuta, Taiga Otsuka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 18, 2014
Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with cautionMasato Yoneda, Emmanuel Thomas, Yoshio Sumida, et al.
Journal of Medical Economics|March 24, 2025
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experimentDaisuke Nakamoto, Yi Piao, Hajime Mizutani, et al.
Alimentary Pharmacology & Therapeutics|September 16, 2021
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver diseaseAtsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Journal of Clinical Biochemistry and Nutrition|April 26, 2008
Radiofrequency ablation with the real-time virtual sonography system for treating hepatocellular carcinoma difficult to detect by ultrasonographyHiroaki Kawasoe, Yuichiro Eguchi, Toshihiko Mizuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 28, 2018
Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver diseaseKenichi Tanaka, Hirokazu Takahashi, Hideyuki Hyogo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 10, 2003
Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1Iwata Ozaki, Toshihiko Mizuta, Gang Zhao, et al.
Pageof 24

Showing results (71-80 of 239) with videos related to

Sort By:
Pageof 24
Digestion|November 19, 2018
Risk Factors for Delayed Hemorrhage after Colonic Endoscopic Mucosal Resection in Patients Not on Antithrombotic Therapy: Retrospective Analysis of 3,844 Polyps of 1,660 PatientsSanae Tsuruta, Naoyuki Tominaga, Shinichi Ogata, et al.
Biochimica Et Biophysica Acta|May 18, 2010
Regulation of tumor suppressor PDCD4 by novel protein kinase C isoformsMayumi Nakashima, Hiroshi Hamajima, Jinghe Xia, et al.
Clinical Biochemistry|May 7, 2014
Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver diseaseMasato Yoneda, Emmanuel Thomas, Yoshio Sumida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 31, 2015
Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatmentSaori Kamachi, Toshihiko Mizuta, Taiga Otsuka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 18, 2014
Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with cautionMasato Yoneda, Emmanuel Thomas, Yoshio Sumida, et al.
Journal of Medical Economics|March 24, 2025
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experimentDaisuke Nakamoto, Yi Piao, Hajime Mizutani, et al.
Alimentary Pharmacology & Therapeutics|September 16, 2021
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver diseaseAtsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Journal of Clinical Biochemistry and Nutrition|April 26, 2008
Radiofrequency ablation with the real-time virtual sonography system for treating hepatocellular carcinoma difficult to detect by ultrasonographyHiroaki Kawasoe, Yuichiro Eguchi, Toshihiko Mizuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 28, 2018
Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver diseaseKenichi Tanaka, Hirokazu Takahashi, Hideyuki Hyogo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 10, 2003
Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1Iwata Ozaki, Toshihiko Mizuta, Gang Zhao, et al.
Pageof 24